New York, New York--(Newsfile Corp. - December 3, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Ginkgo Bioworks Holdings, Inc. ("Ginkgo Bioworks") (NYSE: DNA) between May 11, 2021 and October 5, 2021.
If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
Allegations against DNA include that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) as a result, most, if not all, of the Company's revenue came from related parties the Company created, funded, or controlled through its ownership and board seats; (3) the Company was misclassifying and underreporting related party revenue in order to conceal the Company's near total-dependence on related parties; (4) many of the Company's new R&D partners are undisclosed related parties and/or facades; (5) as a result, the Company's valuation was significant less than Defendants disclosed to investors; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
If you suffered a loss in Ginkgo Bioworks you have until January 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106539